|Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA||Pres, CEO, Sec. & Director||544.76k||N/A||1968|
|Dr. Suzanne T. Ildstad M.D.||Founder, Chief Scientific Officer & Director||486.07k||N/A||1953|
|Ms. Nancy Krieger M.D.||Chief Medical Officer||482.76k||N/A||1967|
|Ms. Mary Kay Fenton||Chief Financial Officer||N/A||N/A||1964|
|Mr. Michael Zdanowski||Chief Technology Officer||N/A||N/A||1967|
|Ms. Suzanne Tollerud||VP of Corp. Devel. & Treasurer||N/A||N/A||N/A|
|Mr. Roderick D. Purdy||VP of HR||N/A||N/A||1957|
|Mr. Eric Gornstein||Head of New Product Planning||N/A||N/A||N/A|
|Ms. Farah Natoli||Head of Portfolio & Program Management||N/A||N/A||N/A|
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Talaris Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.